Compare Spyre Therapeutics Inc. Common Stock (SYRE) vs Consumer Discretionary Select Sector SPDR Fund (XLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Spyre Therapeutics Inc. Common Stock vs Consumer Discretionary Select Sector SPDR Fund — how do they compare? Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.35B), while Consumer Discretionary Select Sector SPDR Fund trades at $111.34 (market cap $21.99B). The key difference: Consumer Discretionary Select Sector SPDR Fund is far larger — about 3× Spyre Therapeutics Inc. Common Stock's market cap, and Spyre Therapeutics Inc. Common Stock is trading nearer its 52-week high, Consumer Discretionary Select Sector SPDR Fund nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Spyre Therapeutics Inc. Common Stock for 0 Days and Consumer Discretionary Select Sector SPDR Fund for 115 Days on average.
| SYRE | XLY | |
|---|---|---|
Market Cap | $7.35B | $21.99B |
Volume | 1,624,631 | 8,302,448 |
Sector | Health | — |
52-Week High | $108.92 | $124.52 |
52-Week Low | $22.18 | $105.64 |
Typical Hold Time | 0 Days | 115 Days |
Enterprise Value | $6.35B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
XLY trades at $112.36, showing minimal daily movement with a 0.07% gain. Technical indicators present a mixed picture with a bullish overall signal but bearish moving averages. Analyst consensus is unanimously positive with 100% buy ratings. The ETF has underperformed the consumer staples sector in 2026, declining over 7% while XLP gained 6.6%, creating a significant performance gap according to State Street data as of September 21, 2026.
The consumer discretionary sector faces headwinds from inflation pressures but benefits from resilient consumer spending and 'funflation' trends. Near-term performance will depend on holiday sales momentum and the sector's ability to overcome persistent underperformance versus the broader market. Key risks include inflation impact on consumer wallets and continued sector rotation away from discretionary spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →About Consumer Discretionary Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: retail; hotels, restaurants and leisure; textiles, apparel and luxury goods; household durables; automobiles; auto components; distributors; leisure products; and diversified consumer services. It is non-diversified.
Read more on XLY →
